Recent developments include multiple analyst buy recommendations, leadership changes, pipeline expansion with new vaccine candidates, and financial restructuring through debt-to-equity conversion.

• Edward Jones initiated coverage of Evaxion A with a buy recommendation in October 2025 [N2].
• HC Wainwright & Co. reiterated and maintained buy recommendations in September and October 2025 [N3][N5].
• Lake Street maintained a buy recommendation in October 2025 [N4].
• Evaxion finalized a €3.5 million debt-to-equity conversion agreement with the European Investment Bank in July 2025, improving capital structure [N6].
• Leadership changes announced in July 2025 included the stepping down of CEO Christian Kanstrup, appointment of Dr. Birgitte Rønø as interim CEO, and Thomas Schmidt as CFO [N7].
• Evaxion added the GAS vaccine candidate EVX-B4 to its pipeline using its AI-Immunology platform in June 2025 [N8].
• The company out-licensed vaccine candidate EVX-B3 to Merck & Co. in September 2025 [N6].
• Multiple news reports in December 2025 highlighted Evaxion among companies gaining post-close [N1].

Evaxion's AI-Immunology platform offers a novel approach to vaccine development, potentially accelerating discovery and improving efficacy. The company's expanding pipeline, including the AI-designed cancer vaccine EVX-01 and the Group A Streptococcus candidate EVX-B4, demonstrates active progress. The out-licensing of EVX-B3 to Merck & Co. indicates commercial interest and potential milestone revenues. Strong liquidity and improved capital structure following the debt-to-equity conversion with the European Investment Bank provide financial flexibility. Positive analyst coverage and buy recommendations reflect market interest and confidence in the company's technology and pipeline.

Evaxion operates in a high-risk clinical-stage environment with significant ongoing losses and no approved products. The company reported a net loss of $7.7 million in 2025 and has an accumulated deficit exceeding $126 million. Clinical development timelines and outcomes are inherently uncertain, and failure in trials could materially impact the business. The company depends heavily on partnerships and licensing agreements for revenue, which may be variable and uncertain. Leadership changes may introduce transitional risks. Additionally, the company faces risks related to funding needs, regulatory approvals, and competition in the biotech sector.

Evaxion's moat is based on its proprietary AI-Immunology platform that leverages artificial intelligence to decode the human immune system and design novel vaccines. This technology-driven approach differentiates the company in the biotech sector, potentially enabling faster and more precise vaccine development. Strategic collaborations, such as the license and research agreement with Merck & Co., provide validation and potential commercial pathways. The company's intellectual property portfolio, including licensed patents, supports its competitive position. However, as a clinical-stage company, the moat is contingent on successful clinical development and regulatory approvals, which remain uncertain.

• Clinical Development Risk: The timing, duration, and success of clinical trials for product candidates are uncertain, which may delay or prevent regulatory approvals.
• Funding and Liquidity Risk: The company has incurred significant losses and depends on external financing and partnerships to fund operations and development activities.
• Partnership and Licensing Risk: Revenue depends on collaborations and licensing agreements, which may be subject to variability in milestone payments and royalties.
• Regulatory and Market Risk: Regulatory approvals are required for commercialization, and market acceptance of new vaccines is uncertain.
• Leadership and Operational Risk: Recent leadership changes may affect strategic execution and operational continuity.

• Evaxion A/S is a clinical-stage TechBio company specializing in AI-Immunology powered vaccines targeting cancer, bacterial diseases, and viral infections.
• The company generates revenue primarily from licenses and services under an option and license agreement and collaborative research agreement with Merck Sharp & Dohme LLC (MSD).
• In 2025, Evaxion recognized $7.5 million in revenue, up from $3.3 million in 2024, mainly due to revenue from the Merck agreement and a grant from the Gates Foundation.
• Research and development expenses were $10.0 million in 2025, slightly down from $10.5 million in 2024, with a decrease in external spending offset by increased employee-related expenses.
• General and administrative expenses decreased to $6.8 million in 2025 from $7.6 million in 2024, mainly due to lower external legal, professional, and capital raise costs.
• The company reported a net loss of $7.7 million in 2025, improved from a $10.6 million loss in 2024.
• Cash and cash equivalents were $23.2 million as of December 31, 2025, up from $6.0 million at the end of 2024, with a strong current ratio of 5.85 and cash ratio of 5.46, indicating solid liquidity.
• Evaxion completed a €3.5 million debt-to-equity conversion with the European Investment Bank in July 2025, improving its capital structure and reducing liabilities.
• The company has an active pipeline including AI-designed cancer vaccine EVX-01 and a Group A Streptococcus vaccine candidate EVX-B4 added in 2025.
• Leadership changes occurred in mid-2025 with the CEO stepping down and an interim CEO appointed, alongside a new CFO.
• Evaxion has ongoing clinical trials, including a Phase 2 extension trial for EVX-01, with recent dosing of the first patient in this extension.
• The company maintains lease agreements for office and laboratory space in Denmark with long-term commitments.
• Evaxion's financial statements are prepared under IFRS and include detailed disclosures on revenue recognition, R&D expenses, finance income and expenses, and tax credits.
• The company recognizes income tax benefits related to R&D tax schemes in Denmark and Australia but has accumulated losses carried forward without deferred tax assets recognized.
• Evaxion's finance income includes gains from derivative liabilities and foreign currency gains, while finance expenses include foreign currency losses and interest expenses related to loans and leases.
• The company monitors liquidity risk and funding needs closely, with management confident in sufficient resources to meet obligations for at least the next 12 months.
• Recent analyst coverage includes buy recommendations and reiterations from multiple firms such as Edward Jones, HC Wainwright & Co., and Lake Street.
• Recent business developments include out-licensing vaccine candidate EVX-B3 to Merck & Co., and launching the EVX-B4 vaccine development program using AI-Immunology platform.